An Open-Label Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of TAK-573 as a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced or Metastatic Solid Tumors
Adult
Treatment
Memorial Hospital Central
Memorial Hospital North
Protocol Number: 21-4364
More information available at ClinicalTrials.gov: NCT04157517
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers